A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement

Thrombosis Research

Volumn 127, Issue 6, 2011, Pages 525-534

  Turun, Song ^a   Banghua, Liao ^a   Yuan, Yin ^a   Zhenhui, Li ^a   Ying, Nie ^a   Jin, Chen ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Enoxaparin; Joint replacement; Prophylaxis; Rivaroxaban; Systematic review; Venous thromboembolism

Indexed keywords

ENOXAPARIN; RIVAROXABAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG SAFETY; EMBOLISM PREVENTION; HIP ARTHROPLASTY; HUMAN; INTRAOCULAR HEMORRHAGE; KNEE ARTHROPLASTY; LONG TERM CARE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL HEMORRHAGE; SHORT COURSE THERAPY; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 79957619172     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.01.016     Document Type: Article

References (40)

1. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991;302:709-11.
2. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis? J R Soc Med 1989;82:203-5.
3. Alikhan R, Peters F, Wilmott R, Cohen AT. Fatal pulmonary embolism in hospitalised patients: A necropsy review. J Clin Pathol 2004;57:1254-7. (Pubitemid 39611508)
4. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factor for deep vein thrombosis and pulmonary embolism: a population based case control study. Arch Intern Med 2001;160:809-15.
5. Anderson Jr FA, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007;82:777-82. (Pubitemid 350194504)
6. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445-53. (Pubitemid 29108909)
7. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
8. Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 1999;99:1325-30. (Pubitemid 29129917)
9. McColl MD, Ellison J, Greer IA, Tait RC, Walker ID. Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism. Br J Haematol 2000;108:272-4. (Pubitemid 30143640)
10. Mohr DN, Silverstein MD, Heit JA, Petterson TM, O'Fallon WM, Melton LJ, et al. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc 2000;75:1249-56.
11. Caprini JA, Botteman MF, Stephens JM, Nadipelli V, Ewing MM, Brandt S, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003;6:59-74. (Pubitemid 36228350)
12. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64.
13. O'Brien JA, Caro JJ. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 2002;20: 603-15.
14. Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E, et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis 2009;29:326-39.
15. Autar R. A review of the evidence for the efficacy of anti-embolism stockings (AES) in venous thromboembolism (VTE) prevention. J Orthop Nurs 2009;13:41-9.
16. Hartmannsgruber MWB, Trent FL, Stolzfus DP. Thrombolytic Therapy for treatment of pulmonary embolism in the postoperative period: case report and review of the literature. Clin Anesth 1996;8:669-74. (Pubitemid 26427840)
17. Galson SK. Prevent deep vein thrombosis and pulmonary embolism with a healthful diet. J Am Diet Assoc 2009;552.
18. Goldhaber SZ, Fanikos J. Prevention of deep vein thrombosis and pulmonary embolism. Circulation 2004;110:e445-7.
19. Cheng R. Prevention and recognition of deep venous thrombosis and pulmonary embolism. Int J Trauma Nurs 1997;91.
20. Rodgers A. Prevention of pulmonary embolism and deep vein thrombosis with low-dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet 2000;355: 1295-302. (Pubitemid 30199000)
21. Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery. Drug 2004;64:577-95.
22. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S-21S.
23. Merli Geno J, Ludwig A. Prophylaxis for deep venous thrombosis and pulmonary embolism in the surgical patient. Deep Venous Thromb 2002;2:15-25.
24. Kolb G, Bodamer I, Galster H, Seidlmayer C, Grambach K, Koudela K, et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprosthetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thromb Haemost 2003;90: 1100-5. (Pubitemid 38004430)
25. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. NEJM 2001;345:1305-10.
26. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1:1504-14.
27. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-21.
28. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80. (Pubitemid 41803696)
29. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-8.
30. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114:2374-81. (Pubitemid 44847454)
31. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. NEJM 2008;358:2765-75. (Pubitemid 351930851)
32. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9.
33. Cai wei. The Study of the Efficacy and Safety of VTE Prophylaxis with Rivaroxaban Following Total Hip Replacement. 2008, doi:CNKI:CDMD:1.2008.087675.
34. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. NEJM 2008;358:2776-86. (Pubitemid 351930852)
35. Turpie AG, Lassen MR, Borris LC, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. Lancet 2009;373:1673-80.
36. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, et al. BAY 59-7939: An oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II doseranging study. J Thromb Haemost 2005;3:2479-86. (Pubitemid 41727165)
37. Rahman S. Deep vein thrombosis prophylaxis: friend or foe. Am J Ther 2009;16: 300-3.
38. Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800. (Pubitemid 29420474)
39. Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9. (Pubitemid 39096017)
40. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and Factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22.